

ALNYLAM PHARMACEUTICALS, INC.

Form 4

January 21, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MARAGANORE JOHN

(Last) (First) (Middle)

C/O ALNYLAM  
PHARMACEUTICALS, INC., 300  
THIRD STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ALNYLAM  
PHARMACEUTICALS, INC.  
[ALNY]

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/19/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |
| Common Stock                    | 01/19/2016                           |  | M <sup>(1)</sup>               |   | 15,076  | A  | \$ 22.75                          |
|                                 |                                      |  |                                |   |   |  | 148,465                           |
| Common Stock                    | 01/19/2016                           |  | S <sup>(1)</sup>               |   | 1,838   | D  | \$ 70.9471                        |
|                                 |                                      |  |                                |   |   |  | 146,627                           |
| Common Stock                    | 01/19/2016                           |  | S <sup>(1)</sup>               |   | 800   | D  | \$ 71.8088                        |
|                                 |                                      |  |                                |   |   |  | 145,827                           |

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

|              |            |                        |        |   |                   |         |         |   |
|--------------|------------|------------------------|--------|---|-------------------|---------|---------|---|
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 1,281  | D | \$<br><u>(4)</u>  | 73.0258 | 144,546 | D |
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 5,112  | D | \$<br><u>(5)</u>  | 74.1379 | 139,434 | D |
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 3,400  | D | \$<br><u>(6)</u>  | 75.0147 | 136,034 | D |
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 2,245  | D | \$<br><u>(7)</u>  | 75.9689 | 133,789 | D |
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 200    | D | \$<br><u>(8)</u>  | 76.95   | 133,589 | D |
| Common Stock | 01/19/2016 | <u>S<sup>(1)</sup></u> | 200    | D | \$<br><u>(9)</u>  | 78.04   | 133,389 | D |
| Common Stock | 01/20/2016 | <u>M<sup>(1)</sup></u> | 15,076 | A | \$                | 22.75   | 148,465 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 1,200  | D | \$<br><u>(10)</u> | 66.2808 | 147,265 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 2,700  | D | \$<br><u>(11)</u> | 67.393  | 144,565 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 4,406  | D | \$<br><u>(12)</u> | 68.351  | 140,159 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 2,114  | D | \$<br><u>(13)</u> | 69.3962 | 138,045 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 930    | D | \$<br><u>(14)</u> | 70.4283 | 137,115 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 1,136  | D | \$<br><u>(15)</u> | 71.7854 | 135,979 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 400    | D | \$<br><u>(16)</u> | 72.5125 | 135,579 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 1,865  | D | \$<br><u>(17)</u> | 73.7677 | 133,714 | D |
| Common Stock | 01/20/2016 | <u>S<sup>(1)</sup></u> | 325    | D | \$<br><u>(18)</u> | 74.6131 | 133,389 | D |



## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2015. The 30,152 options exercised and sold by the reporting person were due to expire on December 14, 2016.
- (2) Sale prices ranged from \$70.40 to \$71.29.
- (3) Sale prices ranged from \$71.41 to \$72.34.
- (4) Sale prices ranged from \$72.55 to \$73.31.
- (5) Sale prices ranged from \$73.60 to \$74.59.
- (6) Sale prices ranged from \$74.64 to \$75.61.
- (7) Sale prices ranged from \$75.76 to \$76.65.
- (8) Sale prices ranged from \$76.82 to \$77.08.
- (9) Sale prices ranged from \$78.01 to \$78.07.
- (10) Sale prices ranged from \$65.81 to \$66.70.
- (11) Sale prices ranged from \$66.81 to \$67.70.
- (12) Sale prices ranged from \$67.92 to \$68.90.
- (13) Sale prices ranged from \$69.00 to \$69.98.
- (14) Sale prices ranged from \$70.05 to \$70.86.
- (15) Sale prices ranged from \$71.06 to \$72.02.
- (16) Sale prices ranged from \$72.20 to \$73.08.
- (17) Sale prices ranged from \$73.38 to \$74.28.
- (18) Sale prices ranged from \$74.43 to \$74.76.
- (19) The reporting person owns 2,750 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- (20) The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.